A yeast-based system to study SARS-CoV-2 M(pro) structure and to identify nirmatrelvir resistant mutations

Mostrar otras versiones (2)

The SARS-CoV-2 main protease (M(pro)) is a major therapeutic target. The M(pro) inhibitor, nirmatrelvir, is the antiviral component of Paxlovid, an orally available treatment for COVID-19. As M(pro) inhibitor use increases, drug resistant mutations will likely emerge. We have established a non-patho...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Jin, Lewandowski, Eric M., Hu, Yanmei, Lipinski, Austin A., Morgan, Ryan T., Jacobs, Lian M.C., Zhang, Xiujun, Bikowitz, Melissa J., Langlais, Paul, Tan, Haozhou, Wang, Jun, Chen, Yu, Choy, John S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387140/
https://www.ncbi.nlm.nih.gov/pubmed/35982672
http://dx.doi.org/10.1101/2022.08.06.503039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387140/
https://www.ncbi.nlm.nih.gov/pubmed/35982672
http://dx.doi.org/10.1101/2022.08.06.503039

Ejemplares similares